Vnitr Lek 2010, 56(10):1043-1049

Clinical and genetic aspects of monogenic obesity

D. Lesayová1,2, J. Staník1,2, D. Gašperíková1,3, I. Klimeš1,3,*
1 DIABGENE a Laboratórium diabetu a porúch metabolizmu ÚEE SAV Bratislava, Slovenská republika, vedúci prof. MUDr. Iwar Klimeš, DrSc.
2 I. detská klinika Lekárskej fakulty UK a Dérerovej FNsP Bratislava, Slovenská republika, prednostka doc. MUDr. Oľga Červeňová, CSc.
3 Molekulárno-medicínske centrum SAV Bratislava, Slovenská republika, riaditeľ MUDr. Richard Imrich, PhD.

High prevalence of obesity in all of age categories is currently one of the biggest problem in medicine. Identification of etiology of obesity can individualise an approach to the patient and it is essential for choosing a target management and therapy. Beside the largest group with polygenic inheritance are clinically important also patients with "syndromic obesity", where obesity is only one of the signs and monogenic obesity, where obesity is the major clinical phenotype (patients with mutations in gene for leptin, leptine receptor, prohormone convertase 1, melanocortine receptor 4, brain-derived neurotropic factor and tyrosin kinase receptor B). The monogenic obesity includes 3-4% of all patients with obesity. This review article brings newest insight on genetics, clinical manifestation, diagnostics and therapy of these diseases.

Keywords: prevalence of obesity; polygenic hereditability of obesity; monogenic obesity

Received: June 28, 2010; Published: October 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lesayová D, Staník J, Gašperíková D, Klimeš I. Clinical and genetic aspects of monogenic obesity. Vnitr Lek. 2010;56(10):1043-1049.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Farooqi S. Obesity genes-it's all about the parents! Cell Metab 2009; 9: 487-488. Go to original source... Go to PubMed...
    2. Farooqi S, O'Rahilly S. Genetics of obesity in humans. Endocr Rev 2006; 27: 710-718. Go to original source... Go to PubMed...
    3. Farooqi S, O'Rahilly S. New advances in the genetics of early onset obesity. Int J Obes (Lond) 2005; 29: 1149-1152. Go to original source... Go to PubMed...
    4. Maes HH, Neale MC, Eaves LJ. Genetic and environmental factors in relative body weight and human adiposity. Behav Genet 1997; 27: 325-351. Go to original source... Go to PubMed...
    5. Meyre D, Lecoeur C, Delplanque J et al. A genome-wide scan for childhood obesity-associated traits in French families shows significant linkage on chromosome 6q22.31-q23.2. Diabetes 2004; 53: 803-811. Go to original source... Go to PubMed...
    6. Stunkard AJ, Sørensen TI, Hanis C et al. An adoption study of human obesity. N Engl J Med 1986; 314: 193-198. Go to original source... Go to PubMed...
    7. Willer CJ, Speliotes EK, Loos RJ et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet 2009; 41: 25-34. Go to original source... Go to PubMed...
    8. Hinney A, Vogel CI, Hebebrand J. From monogenic to polygenic obesity: recent advances. Eur Child Adolesc Psychiatry 2010; 19: 297-310. Go to original source... Go to PubMed...
    9. Hetherington MM, Cecil JE. Gene-environment interactions in obesity. Forum Nutr 2010; 63: 195-203. Go to original source...
    10. O'Rahilly S, Farooqi S. Genetics of obesity. Philos Trans R Soc Lond B Biol Sci 2006; 361: 1095-1105. Go to original source... Go to PubMed...
    11. Santos VM, Henrique de Paula F, Osterne EM et al. Morbid obesity in an adolescent with Prader-Willi syndrome. Rev Med Chil 2009; 137: 264-268. Go to original source...
    12. Ranadive SA, Vaisse C. Lessons from extreme human obesity: monogenic disorders. Endocrinol Metab Clin North Am 2008; 37: 733-751. Go to original source... Go to PubMed...
    13. Tolson KP, Gemelli T, Gautron L et al. Postnatal Sim1 deficiency causes hyperphagic obesity and reduced Mc4r and oxytocin expression. J Neurosci 2010; 30: 3803-3812. Go to original source... Go to PubMed...
    14. Perrone L, Marzuillo P, Grandone A et al. Chromosome 16p11.2 deletions: another piece in the genetic puzzle of childhood obesity. Ital J Pediatr 2010; 36: 43. Go to original source... Go to PubMed...
    15. de Smith AJ, Purmann C, Walters RG et al. A deletion of the HBII-85 class of small nucleolar RNAs (snoRNAs) is associated with hyperphagia, obesity and hypogonadism. Hum Mol Genet 2009; 18: 3257-3265. Go to original source... Go to PubMed...
    16. Farooqi S, O'Rahilly S. Mutations in ligands and receptors of the leptin-melanocortin pathway that lead to obesity. Nat Clin Pract Endocrinol Metab 2008; 4: 569-577. Go to original source... Go to PubMed...
    17. Farooqi S, O'Rahilly S. Monogenic obesity in humans. Annu Rev Med 2005; 56: 443-458. Go to original source... Go to PubMed...
    18. Hochberg I, Hochberg Z. Hypothalamic obesity. Endocr Dev 2010; 17: 185-196. Go to original source... Go to PubMed...
    19. Bochukova EG, Huang N, Keogh J et al. Large, rare chromosomal deletions associated with severe early-onset obesity. Nature 2010; 463: 666-670. Go to original source... Go to PubMed...
    20. Lee YS. The role of leptin-melanocortin system and human weight regulation: lessons from experiments of nature. Ann Acad Med Singapore 2009; 38: 34-41. Go to original source...
    21. Coll AP, Farooqi S, O'Rahilly S. The hormonal control of food intake. Cell 2007; 129: 251-262. Go to original source... Go to PubMed...
    22. Farooqi S. Monogenic human obesity. Front Horm Res 2008; 36: 1-11. Go to original source... Go to PubMed...
    23. Ichihara S, Yamada Y. Genetic factors for human obesity. Cell Mol Life Sci 2008; 65: 1086-1098. Go to original source... Go to PubMed...
    24. Krude H, Grüters A. Implications of proopiomelanocortin (POMC) mutations in humans: the POMC deficiency syndrome. Trends Endocrinol Metab 2000; 11: 15-22. Go to original source... Go to PubMed...
    25. Kimber W, Peelman F, Prieur X et al. Functional characterization of naturally occurring pathogenic mutations in the human leptin receptor. Endocrinology 2008; 149: 6043-6052. Go to original source... Go to PubMed...
    26. Tan K, Pogozheva ID, Yeo GS et al. Functional characterization and structural modeling of obesity associated mutations in the melanocortin 4 receptor. Endocrinology 2009; 150: 114-125. Go to original source... Go to PubMed...
    27. Creemers JW, Lee YS, Oliver RL et al. Mutations in the amino-terminal region of proopiomelanocortin (POMC) in patients with early-onset obesity impair POMC sorting to the regulated secretory pathway. J Clin Endocrinol Metab 2008; 93: 4494-4499. Go to original source... Go to PubMed...
    28. Tan K, Pogozheva ID, Yeo GS et al. Functional characterization and structural modeling of obesity-associated mutations in the Melanocortin 4 Receptor. Endocrinology 2009; 150: 114-125. Go to original source... Go to PubMed...
    29. Kimber W, Peelman F, Prieur X et al. Functional characterisation of naturally occurring pathogenic mutations in the human leptin receptor. Endocrinology 2008; 149: 6043-6052. Go to original source... Go to PubMed...
    30. Farooqi IS, Bullmore E, Keogh J et al. Leptin regulates striatal regions and human eating behavior. Science 2007; 317: 1355. Go to original source... Go to PubMed...
    31. Farooqi S, O'Rahilly S. Leptin: a pivotal regulator of human energy homeostasis. Am J Clin Nutr 2009; 89: 980S-984S. Go to original source... Go to PubMed...
    32. Farooqi S, Jebb SA, Langmack G et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999; 341: 879-884. Go to original source... Go to PubMed...
    33. Farooqi IS, Wangensteen T, Collins S et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med 2007; 356: 237-247. Go to original source... Go to PubMed...
    34. Farooqi S. Insights from the genetics of severe childhood obesity. Horm Res 2007; 68 (Suppl 5): 5-7. Go to original source... Go to PubMed...
    35. Farooqi IS, Matarese G, Lord GM et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002; 110: 1093-1103. Go to original source... Go to PubMed...
    36. Oswal A, Yeo GS. The leptin melanocortin pathway and the control of body weight: lessons from human and murine genetics. Obes Rev 2007; 8: 293-306. Go to original source... Go to PubMed...
    37. Farooqi IS. Monogenic human obesity syndromes. Prog Brain Res 2006; 153: 119-125. Go to original source... Go to PubMed...
    38. Prieur X, Tung YC, Griffin JL et al. Leptin regulates peripheral lipid metabolism primarily through central effects on food intake. Endocrinology 2008; 149: 5432-5439. Go to original source... Go to PubMed...
    39. Guerra B, Santana A, Fuentes T et al. Leptin receptors in human skeletal muscle. J Appl Physiol 2007; 102: 1786-1792. Go to original source... Go to PubMed...
    40. Chan LF, Webb TR, Chung TT et al. MRAP and MRAP2 are bidirectional regulators of the melanocortin receptor family. Proc Natl Acad Sci USA 2009; 106: 6146-6151. Go to original source... Go to PubMed...
    41. Bicknell AB. The tissue-specific processing of pro-opiomelanocortin. J Neuroendocrinol 2008; 20: 692-699. Go to original source... Go to PubMed...
    42. Coll AP, Farooqi IS, Challis BG et al. Proopiomelanocortin and energy balance: insights from human and murine genetics. J Clin Endocrinol Metab 2004; 89: 2557-2562. Go to original source... Go to PubMed...
    43. Krude H, Biebermann H, Luck W et al. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998; 19: 155-157. Go to original source... Go to PubMed...
    44. Nillni EA. Regulation of prohormone convertases in hypothalamic neurons: implications for prothyrotropin-releasing hormone and proopiomelanocortin. Endocrinology 2007; 148: 4191-4200. Go to original source... Go to PubMed...
    45. Bataille D. Pro-protein convertases in intermediary metabolism: islet hormones, brain/gut hormones and integrated physiology. J Mol Med 2007; 85: 673-684. Go to original source... Go to PubMed...
    46. Jackson RS, Creemers JW, Farooqi IS et al. Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J Clin Invest 2003; 112: 1550-1560. Go to original source... Go to PubMed...
    47. O'Rahilly S, Farooqi IS. Human obesity as a heritable disorder of the central control of energy balance. Int J Obes (Lond) 2008; 32 (Suppl 7): S55-S61. Go to original source... Go to PubMed...
    48. Farooqi IS, Volders K, Stanhope R et al. Hyperphagia and early-onset obesity due to a novel homozygous missense mutation in prohormone convertase 1/3. J Clin Endocrinol Metab 2007; 92: 3369-3373. Go to original source... Go to PubMed...
    49. Sundaramurthy D, Campbell DA, Leek JP et al. Assignment of the melanocortin 4 receptor (MC4R) gene to human chromosome band 18q22 by in situ hybridisation and radiation hybrid mapping. Cytogenet Cell Genet 1998; 82: 97-98. Go to original source... Go to PubMed...
    50. Alfieri A, Pasanisi F, Salzano S et al. Functional analysis of melanocortin-4-receptor mutants identified in severely obese subjects living in Southern Italy. Gene 2010; 457: 35-41. Go to original source... Go to PubMed...
    51. Chai B, Li JY, Zhang W et al. Melanocortin-4 receptor activation inhibits c-Jun N-terminal kinase activity and promotes insulin signaling. Peptides 2009; 30: 1098-1104. Go to original source... Go to PubMed...
    52. Masuzaki H, Tanaka T, Ebihara K et al. Hypothalamic melanocortin signaling and leptin resistance - perspective of therapeutic application for obesity-diabetes syndrome. Peptides 2009; 30: 1383-1386. Go to original source... Go to PubMed...
    53. Tao YX. The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocr Rev 2010; 31: 506-543. Go to original source... Go to PubMed...
    54. Farooqi IS, Keogh JM, Yeo GS et al. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 2003; 348: 1085-1095. Go to original source... Go to PubMed...
    55. Lee YS, Poh LK, Kek BL et al. Novel melanocortin 4 receptor gene mutations in severely obese children. Clin Endocrinol (Oxf) 2008; 68: 529-535. Go to original source... Go to PubMed...
    56. Petry CJ, López-Bermejo A, Díaz M et al. Association between a common variant near MC4R and change in body mass index develops by two weeks of age. Horm Res Paediatr 2010; 73: 275-280. Go to original source... Go to PubMed...
    57. Rettenbacher E, Tarnow P, Brumm H et al. A novel non-synonymous mutation in the melanocortin-4 receptor gene (MC4R) in a 2-year-old Austrian girl with extreme obesity. Exp Clin Endocrinol Diabetes 2007; 115: 7-12. Go to original source... Go to PubMed...
    58. Wangensteen T, Kolsgaard ML, Mattingsdal M et al. Mutations in the melanocortin 4 receptor (MC4R) gene in obese patients in Norway. Exp Clin Endocrinol Diabetes 2009; 117: 266-273. Go to original source... Go to PubMed...
    59. Stutzmann F, Tan K, Vatin V et al. Prevalence of melanocortin-4 receptor deficiency in Europeans and their age-dependent penetrance in multigenerational pedigrees. Diabetes 2008; 57: 2511-2518. Go to original source... Go to PubMed...
    60. Maier T, Hoyer J. Modulation of blood pressure by central melanocortinergic pathways. Nephrol Dial Transplant 2010; 25: 674-677. Go to original source... Go to PubMed...
    61. Sayk F, Heutling D, Dodt C et al. Sympathetic function in human carriers of melanocortin-4 receptor gene mutations. J Clin Endocrinol Metab 2010; 95: 1998-2002. Go to original source... Go to PubMed...
    62. Hainerova I, Larsen LH, Holst B et al. Melanocortin 4 receptor mutations in obese Czech children: studies of prevalence, phenotype development, weight reduction response, and functional analysis. J Clin Endocrinol Metab 2007; 92: 3689-3696. Go to original source... Go to PubMed...
    63. Szewczyk JR, Laudeman CP, Sammond DM et al. A concise synthesis of 1,4-dihydro-[1,4]diazepine-5,7-dione, a novel 7-TM receptor ligand core structure with melanocortin receptor agonist activity. Bioorg Med Chem 2010; 18: 1822-1833. Go to original source... Go to PubMed...
    64. Reinehr T, Hebebrand J, Friedel S et al. Lifestyle intervention in obese children with variations in the melanocortin 4 receptor gene. Obesity (Silver Spring) 2009; 17: 382-389. Go to original source... Go to PubMed...
    65. Loos RJ, Rankinen T, Tremblay A et al. Melanocortin-4 receptor gene and physical activity in the Quebec Family Study. Int J Obes (Lond) 2005; 29: 420-428. Go to original source... Go to PubMed...
    66. Price RD, Milne SA, Sharkey J et al. Advances in small molecules promoting neurotrophic function. Pharmacol Ther 2007; 115: 292-306. Go to original source... Go to PubMed...
    67. Dhillo WS. Appetite regulation: an overview. Thyroid 2007; 17: 433-445. Go to original source... Go to PubMed...
    68. Gray J, Yeo GS, Cox JJ et al. Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene. Diabetes 2006; 55: 3366-3371. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.